newsfilter
← Latest News
Business Wire·

CareDx Completes Acquisition of Naveris, Extending Leadership into High-Growth Specialty Oncology

NavDx® is the only Medicare-covered MRD test for HPV-positive Head & Neck and Anal Cancers Expands CareDx’s estimated addressable market to more than $12 billion across transplant, specialty oncology, and cell